← All trials
NCT04217421
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2020
- Primary completion
- Jun 1, 2021
- Completion date
- Jun 1, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 236
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Utrecht UniversityLead sponsor
- Utrecht UniversitySponsor investigator
- Free University of AmsterdamCollaborator
- University of AmsterdamCollaborator
- Erasmus University RotterdamCollaborator
- Leiden UniversityCollaborator
- ZonMw: The Netherlands Organisation for Health Research and DevelopmentCollaborator
- University of GroningenCollaborator
- Radboud UniversityCollaborator
- Utrecht UniversityOverall official - principal investigator
- ACE Pharmaceuticals BVCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.